

Thiazide-Induced Hyponatremia

Kyu Sig Hwang, M.D.
Gheun-Ho Kim, M.D.

Department of Internal Medicine, Hanyang
University College of Medicine, Seoul, Korea

Received : May 4, 2010. Accepted: May 24, 2010

Corresponding author: Gheun-Ho Kim, M.D.

Department of Internal Medicine, Hanyang University
College of Medicine, 17 Haengdang-dong, Seongdong-
gu, Seoul, 133-792, Korea

Tel: +82-2-2290-8318, Fax: +82-2-2298-9183

E-mail: kimgh@hanyang.ac.kr

The importance of thiazide-induced hyponatremia (TIH) is reemerging because thiazide diuretic prescription seems to be increasing after the guidelines recommending thiazides as first-line treatment of essential hypertension have been introduced. Thiazide diuretics act by inhibiting reabsorption of Na⁺ and Cl⁻ from the distal convoluted tubule by blocking the thiazide-sensitive Na⁺/Cl⁻ cotransporter. Thus, they inhibit electrolyte transport in the diluting segment and may impair urinary dilution in some vulnerable groups. Risk factors predisposing to TIH are old age, women, reduced body masses, and concurrent use of other medications that impair water excretion. While taking thiazides, the elderly may have a greater defect in water excretion after a water load compared with young subjects. Hyponatremia is usually induced within 2 weeks of starting the thiazide diuretic, but it can occur any time during thiazide therapy when subsequent contributory factors are complicated, such as reduction of renal function with aging, ingestion of other drugs that affect free water clearance, or changes in water or sodium intake. While some patients are volume depleted on presentation, most appear euvoletic. Notably serum levels of uric acid, creatinine and urea nitrogen are usually normal or low, suggestive of syndrome of inappropriate secretion of antidiuretic hormone. Despite numerous studies, the pathophysiological mechanisms underlying TIH are unclear. Although the traditional view is that diuretic-induced sodium or volume loss results in vasopressin-induced water retention, the following 3 main factors are implicated in TIH: stimulation of vasopressin secretion, reduced free-water clearance, and increased water intake. These factors will be discussed in this review.

Key Words: hyponatremia; thiazides; water; diuretics; vasopressins

Introduction

Thiazide diuretics include all diuretics believed to have a primary action to inhibit NaCl reabsorption in the distal convoluted tubule (Table 1) and have been used in the management of hypertension for over 50 years^{1, 2}. These agents decrease blood pressure (BP) when administered as monotherapy, enhance the efficacy of other antihypertensive agents, and reduce hypertension-related morbidity and mortality. However, the use of

thiazide diuretics is often limited by concerns about some metabolic change, e.g., hyponatremia, hypokalemia and insulin resistance³.

Hyponatremia is an occasional but potentially fatal complication of diuretic therapy. The first detailed description of diuretic-induced hyponatremia was published over 35 years ago⁴. Since that time, numerous additional cases have been reported. Thiazides are a common cause of severe hyponatremia in hospitalized patients⁵ and are associated with high morbidity and

Table 1. Thiazide Diuretics

Thiazide-type (presence of a benzothiadiazine structure)
Chlorothiazide
Hydrochlorothiazide
Methylclothiazide
Polythiazide
Bendroflumethiazide
Thiazide-like (mechanism of action similar to that of thiazide-type diuretics)
Metolazone
Chlorthalidone
Indapamide

mortality^{6,7}.

Virtually all cases of severe diuretic-induced hyponatremia have been due to a thiazide-type diuretic⁶⁻¹². In contrast, loop diuretics are implicated much less commonly⁷. This observation is probably derived from the different nephronal sites of action of these two classes of diuretics. Thiazide diuretics inhibit NaCl reabsorption in the distal convoluted tubule, the main diluting site of the nephron. Thus, thiazide diuretics interfere with maximum dilution of urine because sodium (Na⁺) excretion is increased along with diminished free-water excretion^{13, 14}. On the other hand, loop diuretics inhibit NaCl reabsorption in the thick ascending limb of the loop of Henle. The reabsorption of NaCl without water in the medullary thick ascending limb is normally the primary step in the generation of the hypertonicity in the medullary interstitium, and loop diuretics mainly impair urinary concentration and limit water retention and development of hyponatremia¹⁵.

Although thiazide diuretics are frequently recommended as the first-line anti-hypertensive according to the practice guidelines and results of the major clinical trials such as the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)¹⁶⁻¹⁸, the mechanism and optimal treatment of thiazide-induced hyponatremia (TIH) remain unclear. In this review, we will explore the pathogenesis, discuss the clinical features, and suggest an approach to the treatment of TIH.

Epidemiology of TIH

Electrolyte disturbance is common after administration of thiazide diuretics, and hyponatremia is a typical complication with an estimated incidence of 11% in one series of 114 geriatric patients¹⁹. In the Systolic Hypertension in the Elderly Program (SHEP), which focused on older patients, hyponatremia was observed in 4.1% of patients treated with chlorthalidone versus 1.3% in the control group²⁰. Thirty percent of patients were receiving 12.5 mg/day of chlorthalidone, and 60% were receiving 25 mg/day²⁰. In another study on elderly patients, diuretic-induced hyponatremia was seen in 17% and hypokalemia in 6.6%²¹. Fifty three percent of patients were receiving a thiazide diuretic and 24% a loop diuretic²¹. In patients with TIH, an average daily hydrochlorothiazide dose of 35 mg has been reported, with 44% of patients having received ≥ 50 mg²². On the other hand, in 10% of the cases with TIH the dose was only 12.5 mg²³. Considering the high prevalence of hypertension in the elderly and the routine use of thiazide diuretics to treat it, TIH is clearly a prevalent problem.

The question arises as to whether a certain subgroup of patients is susceptible to this adverse effect of thiazides. The risk factors of TIH are old age, women, reduced body mass^{7, 9, 13, 14, 22, 24}, and concurrent use of other medications that impair water excretion^{13, 25}. As shown in Table 2 which was obtained by the recent nephrology consultation in our hospital, old women are clearly predisposed to TIH.

According to the experiment done by Clark et al.¹³, healthy elderly subjects do not excrete free water as efficiently as younger ones do. In particular, elderly subjects with a previous history of TIH have impaired urinary dilution capacity, and hence, increased susceptibility to TIH. Among the explanations, blunted prostaglandin synthesis is an attractive possibility²⁵, and could result from aging or propensity among the elderly for polypharmacy, including non-steroidal anti-inflammatory agents.

The reason why individuals with reduced body mass are more prone to complications from diuretics remains

puzzling. Plasma Na⁺ level is determined by the ratio between the amount of exchangeable Na⁺ and potassium (K⁺) and the total body water²⁶. Thus, it is conceivable that Na⁺ concentration might change to a greater degree in a subject with smaller body size, and hence less total body water. Besides, small body mass or muscle wasting might also signify underlying illness²⁷.

Numerous case reports have indicated that hypertensive women are particularly at risk to develop hyponatremia^{7, 9, 13, 14, 22, 24}. The reason that women are more susceptible to the effects of thiazide diuretics than men is unknown. Women probably drink more than men to compensate for the diuretic and therefore develop more dilutional hyponatremia²⁸, and hypertensive women may be more often treated with diuretics than hypertensive men²⁹. Moreover, women may be more symptomatic than men at comparable serum Na⁺ levels and therefore may be diagnosed more often than men³⁰.

Clinical characteristics of TIH

The clinical manifestations of TIH are similar to those due to other causes of hyponatremia. TIH can develop acutely or gradually. It can range from mild to severe and from asymptomatic to symptomatic. One of the most remarkable features of TIH is the rapidity with which it can occur. In susceptible individuals, the serum Na⁺ may fall within hours of administration⁸, and severe hyponatremia can develop within less than 2 days^{7, 14}. In most reported cases (50% to 90%) the duration of thiazide use was less than 2 weeks^{7, 8, 14, 22}. However it can occur any time during thiazide therapy when sub-sequent contributory factors are complicated such as old age, increased water intake, low salt intake^{7, 9, 13, 14, 22, 24}, and concurrent use of other medications that impair water excretion^{13, 25}.

Mild hyponatremia, with serum Na⁺ concentration in the range of 125 to 132 mEq/L, is usually asymptomatic, although vague symptoms such as fatigue or nausea are possible³. More severe hyponatremia, as reported in patients who required hospitalization, can be asymptomatic

or associated with symptoms including weakness, vomiting, nausea, confusion, dizziness, abdominal pain, and manifestations as serious as lethargy, seizures, and coma^{11, 22}.

The volume status of TIH may be variable. While some patients are volume depleted on presentation, most appear to be euvolemic^{10, 14, 31, 32}. Reduced free-water clearance can explain why many patients with TIH behave as if they are volume expanded; the body weight may initially increase⁸. In patients with TIH, blood urea nitrogen (BUN) and plasma creatinine concentration are generally low-normal^{10, 33}, and hypouricemia due to enhanced urinary uric acid excretion may be present^{32, 33}. All of these findings are similar to those in the syndrome of inappropriate antidiuretic hormone secretion (SIADH), which is also associated with initial volume expansion. The laboratory data from our TIH patients are also compatible with those of SIADH (Table 2), similarly to reports from other studies^{8-11, 13}. According to Sonnenblick et al.³², elevated fractional uric acid clearance and low serum uric acid level were useful to determine that TIH was more favored than furosemide-induced hyponatremia.

Pathogenesis of TIH

Despite numerous studies, the pathophysiological mechanisms underlying TIH are unclear. Although the traditional view is that diuretic-induced Na⁺ or volume

Table 2. Data from Patients (n=14) with Hydrochlorothiazide-Induced Hyponatremia

Gender (M/F)	0 / 14
Age (years)	78±6 (62-87)
Serum Na ⁺ (mEq/L)	118±6 (106-128)
Serum osmolality (mOsm/kg)	241±11 (221-256)
Serum K ⁺ (mEq/L)	3.5±0.6 (2.2-4.1)
Serum Cl ⁻ (mEq/L)	82±8 (70-96)
Serum total CO ₂ (mEq/L)	23.4±2.8 (20.1-28.4)
Urine osmolality (mOsm/kg)	391±119 (215-584)
Urine Na ⁺ (mEq/L)	91±51 (15-194)
BUN (mg/dL)	12±4 (7-18)
Serum creatinine (mg/dL)	0.7±0.2 (0.4-1.1)
Serum uric acid (mg/dL)	3.1±1.0 (1.5-4.9)

Continuous parameters are described as mean±SD (range). BUN, blood urea nitrogen.

Table 3. Contributory Factors for Thiazide-Induced Hyponatremia

1. Excess free-water intake
Increased water intake
Low salt intake
2. Reduced free-water clearance
Reduced renal capacity to excrete free-water, usually age-related
Stimulation of vasopressin release
Ingestion of other drugs that impair free-water clearance
3. Renal Na ⁺ and/or K ⁺ loss.

loss results in vasopressin-induced water retention, the following 3 main factors are implicated in TIH: increased water intake, reduced free-water clearance and renal Na⁺ and/or K⁺ loss (Table 3).

There is evidence that water intake is maintained or increased in many patients with TIH^{6, 8, 27}. Friedman et al.⁸ showed that within 6 hours of ingesting a single hydrochlorothiazide-amiloride tablet, previously affected patients had a small rise in urine osmolality and a fall in serum Na⁺ of 5.5 mEq/L in association with a small gain in weight; controls had only a slight fall in serum Na⁺, and their mean weight fell. Although water intake was not measured, the authors suggested that thiazides might cause polydipsia, which, when combined with the renal effects, results in expansion of total body water and development of hyponatremia. Stimulation of water intake would not only help defend the extracellular volume, but would also explain why thiazides are one of the most common causes of severe hyponatremia.

Increased water intake would not lead to hyponatremia unless impairment in water excretion exists. While thiazide diuretics do not inhibit concentrating ability, they do impair diluting ability in several ways^{15, 26, 34}. As mentioned above, they inhibit electrolyte transport at the cortical diluting sites, thereby raising the minimum urinary osmolality³⁴⁻³⁶. Diuretics may also reduce glomerular filtration rate and enhance reabsorption of Na⁺ and water in the proximal nephron, diminishing fluid delivery to the distal diluting sites³⁵. Thus, water can be retained independent of serum osmolality. Besides, thiazide-induced volume depletion probably contributes to the genesis of TIH in some cases. Hypovolemia may stimulate the release of vasopressin because non-osmotic vasopressin secretion is

very common in normovolemic and hypovolemic types of hyponatremia³¹.

Thiazides may directly affect water permeability in the collecting duct epithelia³⁷. A previous *in vitro* microperfusion study showed that hydrochlorothiazide enhanced water absorption in the inner medullary collecting duct from normal rats and Brattleboro rats as well³⁸. Consistent with this, Kim et al. reported that the paradoxical antidiuresis induced by hydrochlorothiazide in nephrogenic diabetes insipidus was associated with upregulation of aquaporin-2 in the collecting duct³⁹.

There is much evidence that patients with TIH are electrolyte-deficient. First, virtually all relevant studies have found that during the development of TIH, Na⁺ balance is negative^{4, 6, 10}. Fuisz et al. argued that changes in external Na⁺ and water balance did not completely account for the fall in serum Na⁺⁴. Furthermore, chlorothiazide induced hyponatremia in their patients despite Na⁺ supplementation and positive Na⁺ balance. These observations led the authors to conclude that a shift of Na⁺ into the intracellular space contributed to the pathogenesis of hyponatremia. Second, once diuretics are withdrawn, urinary Na⁺ excretion falls to very low levels^{4, 10}. Third, many of these patients are hypokalemic^{4, 6, 10}. Fichman et al.¹⁰ emphasized the importance of K⁺ depletion in TIH. The great majority of their 25 patients was hypokalemic, and hyponatremia was corrected in 4 of them by K⁺ repletion despite continued diuretic use and Na⁺ restriction. These investigators argued that K⁺ depletion predisposes the patients to hyponatremia because the serum Na⁺ concentration is dependent upon the ratio of the sum of exchangeable Na⁺ and K⁺ to total body water. They also speculated that K⁺ depletion might cause a shift of Na⁺ into the intracellular space, thereby further compromising the extracellular volume and stimulating vasopressin release. Na⁺ and/or K⁺ depletion alone would not be expected to cause marked hyponatremia because water excretion normally increases as the serum Na⁺ concentration falls. However, because thiazides interfere with renal water excretion, they impair this normal

osmoregulatory response. Thus, as in most patients with hyponatremia, urine osmolality is inappropriately high relative to the osmolality of plasma and often exceeds it^{4,6,10,31,32}.

Several drugs increase the likelihood of developing TIH. Nonsteroidal anti-inflammatory drugs, through prostaglandin inhibition, decrease free-water clearance^{13,25}. Drugs such as chlorpropamide or selective serotonin reuptake inhibitors may be associated with SIADH³. Polydipsia caused by psychotropic medications also predisposes to TIH³.

Management of TIH

The acute management of TIH is more determined by the presence or absence of neurologic symptoms than by the Na⁺ level per se. Treatment consists of discontinuing thiazides, regular diet (usually supplemented with K⁺) restricting water, administration of furosemide and either isotonic saline or, if the hyponatremia is severe or symptomatic, hypertonic saline.

In patients with hypovolemic TIH, in whom vasopressin secretion stimulated by hypovolemia contributes to the inability to excrete free water, normal saline infusion is appropriate because it will restore volume and suppress vasopressin release. In patients with severe manifestations such as seizures or coma, initiation of treatment with hypertonic saline to assure rapid onset of response is recommended^{13,16}. We treated our patients with TIH using

either isotonic or 3% hypertonic saline (Table 4). The data suggest that the severity of hyponatremia might influence the choice between isotonic and hypertonic saline.

In patients with euvoemia or hypervolemia-associated hyponatremia, who tend to have lower serum levels of uric acid, BUN, and creatinine, normal saline will not restore free-water clearance or serum Na⁺ concentration. In such patients, hypertonic saline will predictably raise serum Na⁺ concentration and is preferable. Administration of furosemide in addition to the hypertonic saline can increase free-water clearance and thus hasten the increase of the serum Na⁺ concentration while avoiding volume overload⁵.

In asymptomatic or minimally symptomatic patients, stopping the offending diuretic and restricting water intake to <1 L/day is usually all that is needed. Normal saline is not needed unless correction of volume depletion is indicated. Increasing oral salt intake in combination with fluid restriction can increase serum Na⁺ concentration³.

Prevention of TIH

How can TIH be prevented? There are no guidelines regarding measures to prevent TIH. The first step in prevention of TIH is awareness that it can happen, particularly in the elderly, female, or small individuals. In susceptible individuals, the serum Na⁺ may fall in hours of diuretic ingestion, and severe hyponatremia can develop within 2 days^{7,14}. Therefore in susceptible patients, serum Na⁺ should be measured within one day after beginning therapy. If the serum Na⁺ level falls more than a few mEq/L, the diuretic should be stopped. If there is little or no change in the serum Na⁺, it should be rechecked 1-2 days later to be sure the level is stable¹⁴.

Identifying patients with excessive fluid intake and counseling them to reduce their intake would be extremely helpful and cost-effective. When prescribing thiazides, low doses should be used³. Only 10% of TIH cases occur at low dosage^{19,20,22}. A lower dose would increase the ability to excrete free-water, would reduce the hypovolemic

Table 4. Comparison of Biochemical Data According to Saline Preparations Used in Treatment of Thiazide-Induced Hyponatremia

	Hypertonic saline (n=5)	Isotonic saline (n=9)	P*
Serum Na ⁺ (mEq/L)	112±4	121±5	0.009
Serum K ⁺ (mEq/L)	3.5±0.4	3.5±0.7	NS
Serum total CO ₂ (mEq/L)	21.9±1.6	24.2±3.1	NS
BUN (mg/dL)	12±4	12±4	NS
Uric acid (mg/dL)	3.4±1.0	2.9±1.0	NS
Urine osmolality (mOsm/kg)	478±117	343±94	0.053
Urine Na ⁺ (mEq/L)	96±63	88±47	NS

Data are presented as mean±SD.

BUN, blood urea nitrogen; NS, not significant.

* Comparison was performed by Mann-Whitney U test.

stimulus for vasopressin secretion, and can correct borderline hyponatremia in many cases³). Even patients who have done well on chronic thiazide therapy may develop severe hyponatremia if water intake increases. Therefore, all patients using these drugs should be educated about the danger of drinking excessive water^{3, 14}).

Acknowledgements

This study was supported by a grant from Fresenius Medical Care Korea, 2009.

References

- 1) Freis ED, Wanko A, Wilson IM, Parrish AE: Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. *J Am Med Assoc* 166:137-140, 1958
- 2) Moser M, Macaulay AI: Chlorothiazide as an adjunct in the treatment of essential hypertension. *Am J Cardiol* 3:214-219, 1959
- 3) Mann SJ: The silent epidemic of thiazide-induced hyponatremia. *J Clin Hypertens (Greenwich)* 10:477-484, 2008
- 4) Fuisz RE, Lauler DP, Cohen P: Diuretic-induced hyponatremia and sustained antidiuresis. *Am J Med* 33:783-791, 1962
- 5) Adrogue HJ, Madias NE: Hyponatremia. *N Engl J Med* 342:1581-1589, 2000
- 6) Ashraf N, Locksley R, Arieff AI: Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. *Am J Med* 70:1163-1168, 1981
- 7) Sonnenblick M, Friedlander Y, Rosin AJ: Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. *Chest* 103:601-606, 1993
- 8) Friedman E, Shadel M, Halkin H, Farfel Z: Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. *Ann Intern Med* 110:24-30, 1989
- 9) Chow KM, Szeto CC, Wong TY, Leung CB, Li PK: Risk factors for thiazide-induced hyponatraemia. *QJM* 96:911-917, 2003
- 10) Fichman MP, Vorherr H, Kleeman CR, Telfer N: Diuretic-induced hyponatremia. *Ann Intern Med* 75:853-863, 1971
- 11) Chow KM, Kwan BC, Szeto CC: Clinical studies of thiazide-induced hyponatremia. *J Natl Med Assoc* 96:1305-1308, 2004
- 12) Ernst ME, Moser M: Use of diuretics in patients with hypertension. *N Engl J Med* 361:2153-2164, 2009
- 13) Clark BA, Shannon RP, Rosa RM, Epstein FH: Increased susceptibility to thiazide-induced hyponatremia in the elderly. *J Am Soc Nephrol* 5:1106-1111, 1994
- 14) Spital A: Diuretic-induced hyponatremia. *Am J Nephrol* 19:447-452, 1999
- 15) Szatalowicz VL, Miller PD, Lacher JW, Gordon JA, Schrier RW: Comparative effect of diuretics on renal water excretion in hyponatraemic oedematous disorders. *Clin Sci (Lond)* 62:235-238, 1982
- 16) Lenfant C, Chobanian AV, Jones DW, Roccella EJ: Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. *Hypertension* 41:1178-1179, 2003
- 17) Williams B, Poulter NR, Brown MJ, et al.: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens* 18:139-185, 2004
- 18) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 288:2981-2997, 2002
- 19) Byatt CM, Millard PH, Levin GE: Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. *J R Soc Med* 83:704-708, 1990
- 20) SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 265:3255-3264, 1991
- 21) Sunderam SG, Mankikar GD: Hyponatraemia in the elderly. *Age Ageing* 12:77-80, 1983
- 22) Sharabi Y, Illan R, Kamari Y, et al.: Diuretic-induced hyponatraemia in elderly hypertensive women. *J Hum Hypertens* 16:631-635, 2002
- 23) Sonnenblick M, Algur N, Rosin A: Thiazide-induced hyponatremia and vasopressin release. *Ann Intern Med* 110:751, 1989
- 24) Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP: Thiazide diuretic prescription and electrolyte abnormalities in primary care. *Br J Clin Pharmacol* 61: 87-95, 2006
- 25) Walker RM, Brown RS, Stoff JS: Role of renal prostaglandins during antidiuresis and water diuresis in man. *Kidney Int* 21:365-370, 1982
- 26) Rose BD: New approach to disturbances in the plasma sodium concentration. *Am J Med* 81:1033-1040, 1986
- 27) Abramow M, Cogan E: Clinical aspects and pathophysiology of diuretic-induced hyponatremia. *Adv Nephrol Necker Hosp* 13:1-28, 1984

- 28) Kone B, Gimenez L, Watson AJ: Thiazide-induced hyponatremia. *South Med J* 79:1456-1457, 1986
- 29) Klungel OH, de Boer A, Paes AH, Seidell JC, Bakker A: Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. *J Hypertens* 15:591-600, 1997
- 30) Ayus JC, Wheeler JM, Arieff AI: Postoperative hyponatremic encephalopathy in menstruant women. *Ann Intern Med* 117:891-897, 1992
- 31) Ghose RR: Plasma arginine vasopressin in hyponatraemic patients receiving diuretics. *Postgrad Med J* 61:1043-1046, 1985
- 32) Sonnenblick M, Rosin AJ: Significance of the measurement of uric acid fractional clearance in diuretic induced hyponatraemia. *Postgrad Med J* 62:449-452, 1986
- 33) Decaux G, Schlessler M, Coffernils M, et al.: Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. *Clin Nephrol* 42:102-108, 1994
- 34) Seldin DW, Eknayan G, Suki WN, Rector FC, Jr.: Localization of diuretic action from the pattern of water and electrolyte excretion. *Ann NY Acad Sci* 139:328-343, 1966
- 35) Earley LE, Kahn M, Orloff J: The effects of infusions of chlorothiazide on urinary dilution and concentration in the dog. *J Clin Invest* 40:857-866, 1961
- 36) Heinemann HO, Demartini FE, Laragh JH: The effect of chlorothiazide on renal excretion of electrolytes and free water. *Am J Med* 26:853-861, 1959
- 37) Calesnick B, Brenner SA: An observation of hydrochlorothiazide in diabetes insipidus. *JAMA* 176:1088-1091, 1961
- 38) Cesar KR, Magaldi AJ: Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. *Am J Physiol* 277:F756-760, 1999
- 39) Kim GH, Lee JW, Oh YK, et al.: Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. *J Am Soc Nephrol* 15:2836-2843, 2004